Altre lingue Microba Life Sciences Limited

Azioni

MAP

AU0000209868

Mercato chiuso - Australian S.E. Altri mercati azionari 08:10:25 12/07/2024			Variaz. 5gg	Var. 1 gen.
0,175 ^AUD	+4,48%		+2,94%	-2,78%

28/06	Microba Life Sciences completa lo screening del programma per le malattie autoimmuni; le azioni scendono del 3%.	MT
10/04	Microba Life Sciences ottiene un rimborso fiscale di 6 milioni di dollari australiani per l'anno fiscale 2023; le azioni scendono del 5%.	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Microba Life Sciences Completes Screening for Autoimmune Disease Program; Shares Down 3%	28/06
Microba's Revenue Climbs 297% in Fiscal Q3	23/04
Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5%	10/04
2,700,000 Options of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-APR-2024.	05/04
48,031,314 Ordinary Shares of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-APR-2024.	05/04
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data	13/03
Microba Life Sciences Rise 9% Following Launch of MetaPanel Test With Sonic Healthcare	13/03
Microba Life Sciences Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02
8,250,000 Options of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	05/02
54,500,297 Ordinary Shares of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 27-JAN-2024.	27/01
Weak Oil Prices, China's Property Woes Hold Down Australian Shares	07/12
Microba Life Sciences Validates Safety, Tolerability of Inflammatory Bowel Disease Therapy in Phase One Trial	07/12
Microba Life Sciences Completes Acquisition of UK Microbiome Testing Company; Shares Slide 5%	06/12
Microba Life Sciences Limited completed the acquisition of Invivo Clinical Limited.	05/12
Microba Life Sciences Signs Research Agreement with IFF Subsidiary to Develop Allergy Treatments	04/12
Microba Life Sciences' Domestica, International Personal Testing Revenue Rises in Fiscal Q1	19/10/23
Microba Life Sciences to Acquire Invivo Clinical	19/10/23
Microba Life Sciences Limited signed a binding share purchase agreement to acquire Invivo Clinical Limited for £11 million.	19/10/23
Microba Life Sciences Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23
Microba Life Sciences Completes Dosing for Phase One Trial of Biotherapeutic Product	25/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Microba Life Sciences Limited

Azioni

MAP

AU0000209868

Altre lingue

Filtri